NASDAQ:QURE
uniQure N.V. Stock News
$5.20
-0.210 (-3.88%)
At Close: Mar 28, 2024
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
09:20am, Wednesday, 28'th Feb 2024
UniQure (QURE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to earnings of $0.15 per share a year ago.
3 Micro-Cap Stocks That Could Be Moonshots
10:31pm, Tuesday, 14'th Nov 2023
Amid the valuations of large-cap stocks, notably tech stocks in the Magnificent 7 declining, this has led to this list of micro-cap stocks. Not only are investors expected to rotate into smaller and u
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
09:46am, Tuesday, 07'th Nov 2023
UniQure (QURE) came out with a quarterly loss of $1.88 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.02 per share a year ago.
uniQure (QURE) Up on Restructuring Plans, Workforce Reduction
12:47pm, Friday, 06'th Oct 2023
uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.
Why Shares of uniQure Are Up Thursday
01:49pm, Thursday, 05'th Oct 2023
uniQure said it is cutting back 28% of its workforce. The company is discontinuing much of its pipeline to focus on more promising therapies.
uniQure slashes more than half of its research programs to preserve cash
12:21pm, Thursday, 05'th Oct 2023
Gene therapy-focused biotechnology firm uniQure announced it is slashing more than half of its research and technology projects as part of a strategic reorganization aimed at reducing its operating e
UniQure to cut 28% of workforce and scrap more than half its research projects in strategic overhaul
08:18am, Thursday, 05'th Oct 2023
UniQure N.V. QURE, -4.74%, a gene therapy company focused on developing therapies for patients with severe medical needs, said Thursday it's planning a strategic overhaul that will cut 28% of its work
Why Shares of uniQure Are Dropping Tuesday
01:10pm, Tuesday, 05'th Sep 2023
The Food and Drug Administration has cleared uniQure's application for an epilepsy therapy. The company grew revenue in the second quarter by 380%, year over year.
3 Tantalizing Stocks to Buy for Under $10
03:51pm, Saturday, 26'th Aug 2023
As a rule of thumb, you should avoid targeting cheap securities, However, exceptions can always be made, particularly for these tantalizing stocks under $10 to buy. To be sure, the cheap ideas in the
UniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
10:25am, Tuesday, 01'st Aug 2023
UniQure (QURE) came out with a quarterly loss of $1.44 per share versus the Zacks Consensus Estimate of $2.97. This compares to loss of $0.84 per share a year ago.
Why uniQure Stock Cratered This Week
03:03pm, Thursday, 22'nd Jun 2023
Wednesday, uniQure announced interim phase 1/2 results for its experimental Huntington's disease gene therapy. Results from the high-dose cohort raised more questions than they answered.
uniQure (QURE) Falls on Mixed Huntington's Disease Study Results
11:51am, Thursday, 22'nd Jun 2023
uniQure (QURE) stock declines after the company announces mixed results from its biomarkers analysis in the early-to-mid-stage study of AMT-130 in Huntington's disease.
Why uniQure Stock Is Crashing Today
11:46am, Wednesday, 21'st Jun 2023
uniQure reported interim data from a phase 1/2 study of AMT-130 in treating Huntington's disease. The results for the low dose of the gene therapy were promising.
uniQure: Financials And Pipeline Signal A Promising Outlook For Investors
09:19am, Saturday, 20'th May 2023
uniQure's strong financial performance and remarkable revenue growth highlight the company's continued upward trajectory, making it a promising investment opportunity. Innovative gene therapies such a
UniQure (QURE) Reports Q1 Loss, Lags Revenue Estimates
09:56am, Tuesday, 09'th May 2023
UniQure (QURE) came out with a quarterly loss of $1.63 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $1 per share a year ago.